Description: Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. The company also owns and operates multidisciplinary clinics that offers treatment of mental health disorders. In addition, it is involved in the research activities related to discovering and commercializing novel drugs and delivery methods; and development and acquisition of derivatives of ketamine and psilocybin, as well as other psychedelic products from its IP development platform. The company is headquartered in Toronto, Ontario.
Home Page: braxiascientific.com
700 Bay Street
Toronto,
ON
M5G 1Z6
Canada
Phone:
416-430-9619
Officers
| Name | Title |
|---|---|
| Mr. Peter Rizakos | CFO & Director |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.5956 |
| Price-to-Sales TTM: | 0.4259 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |